Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brainfunctions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

Biotechnology

Therapeutics

Embera NeuroTherapeutics

Bob Linke

Ross Barrett

Lawrence Yarmaloff

Julie Ann Straub

Gary Connor

Bruce McCarthy

The Advisory and Science Team at Embera NeuroTherapeutics is responsible for providing strategic guidance and scientific expertise to drive the development of novel addiction treatments, including EMB-001. This team leverages breakthrough research to inform clinical strategies, refine the therapeutic approach, and ensure the efficacy and safety of treatments targeting smoking cessation and other addictions.

Advisory and Science Team

Leadership Team

Advisory and Science Team

About

Team members